Trials / Recruiting
RecruitingNCT07122076
GT719 Injection for Moderate to Severe Refractory Autoimmune Diseases
A Single-arm, Open-label Clinical Study of GT719 Injection for Moderate to Severe Refractory Autoimmune Diseases
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Grit Biotechnology · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study is a prospective single-arm open-label clinical trial, aims to evaluate the safety, efficacy, and cellular pharmacokinetics of GT719 Injection in patients with moderate to severe refractory autoimmune diseases. A total of 10 subjects will be enrolled in this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GT719 Injection | GT719 Injection |
Timeline
- Start date
- 2025-08-22
- Primary completion
- 2028-08-21
- Completion
- 2028-08-21
- First posted
- 2025-08-14
- Last updated
- 2025-09-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07122076. Inclusion in this directory is not an endorsement.